TXNIP在乳腺癌中的表达及临床意义

目的 探讨硫氧还蛋白结合蛋白（TXNIP）在乳腺癌组织中的表达及临床意义。方法 收集2011年至2012年50例乳腺癌组织及对应癌旁组织，采用qRT-PCR、Western blotting及免疫组化法分别检测16例、7例和50例乳腺癌及对应癌旁组织中TXNIP mRNA表达量、蛋白水平及蛋白阳性表达情况，并分析TXNIP表达与乳腺癌临床病理特征的关系。结果 乳腺癌组织中TXNIP mRNA表达量为39.07±12.34，癌旁组织中为40.12±13.13（P＞0.05）；乳腺癌组织中TXNIP蛋白水平和阳性表达率分别为0.43±0.11和52.0％，均低于癌旁组织的0.85±0.01和72.0％，差异均有统计学意义（P＜0.05）。TXNIP蛋白表达与乳腺癌TNM分期和分化程度有关（P＜0.05），Ⅲ、Ⅳ期及低分化乳腺癌组织中TXNIP蛋白阳性表达率低于其对应癌旁组织（P＜0.05）。结论 TXNIP在乳腺癌组织及癌旁组织中表达存在差异，其可能成为乳腺癌诊断和治疗的参考指标。

Expression of TXNIP in breast cancer and its clinical significance

Objective To explore the expression of thioredoxin interacting protein（TXNIP） in breast cancer and its clinical sig- Fifty samples of breast cancer tissues and the corresponding adjacent non-cancerous tissues were collected from 2011 to 2012. The quantitative reverse transeription-PCR（ qRT-PCR）, Western blotting and immunohistochemical method were used to detect the TXNIP mRNA, protein level and positive expression rate in 16, 7 and 50 samples of breast cancer tissues and the correspond- ing adjacent non-cancerous tissues, respectively. The relationship between the expression of TXNIP and its clinicopathological features in breast cancer was also investigated. Results There was no significam difference between breast cancer tissues and adjacent non-cancer- ous tissues in mRNA level of TXNIP（39. 07± 12. 34 vs. 40. 12± 13. 13, P 〉0. 05）. The protein level and positive expression rate of TX- NIP in breast cancer tissues were 0. 43±0. 11 and 52. 0%, lower than 0. 85 ±0. 01 and 72. 0% in adjacent non-cancerous tissues（P 〈 0. 05）. There were statistically significant differences of TXNIP expression among different TNM staging and the degree of differentiation in breast cancer tissues, and the positive expression rate of TNM stage Ⅲ-Ⅳ and low differentiation in adjacent non-cancerous tissues were superior to that in breast cancer tissues（P 〈 0. 05 ）. Conclusion There are different expressions of TXNIP in breast cancer tissues and adjacent non-cancerous tissues, and TXNIP may be a reference for diagnosis and treatment in breast cancer.